Related Experiment Video
Updated: Feb 7, 2026

Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
Published on: November 3, 2014
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Israel Cañadas1, Rohit Thummalapalli1, Jong Wook Kim1,2
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Mesenchymal tumor subpopulations secrete pro-tumorigenic cytokines and promote treatment resistance1-4. This phenomenon has been implicated in chemorefractory small cell lung cancer and resistance to targeted therapies5-8, but remains incompletely defined. Here, we identify a subclass of endogenous retroviruses (ERVs) that engages innate immune signaling in these cells. Stimulated 3 prime antisense retroviral coding sequences (SPARCS) are oriented inversely in 3' untranslated regions of specific genes enriched for regulation by STAT1 and EZH2. Derepression of these loci results in double-stranded RNA generation following IFN-γ exposure due to bi-directional transcription from the STAT1-activated gene promoter and the 5' long terminal repeat of the antisense ERV. Engagement of MAVS and STING activates downstream TBK1, IRF3, and STAT1 signaling, sustaining a positive feedback loop. SPARCS induction in human tumors is tightly associated with major histocompatibility complex class 1 expression, mesenchymal markers, and downregulation of chromatin modifying enzymes, including EZH2. Analysis of cell lines with high inducible SPARCS expression reveals strong association with an AXL/MET-positive mesenchymal cell state. While SPARCS-high tumors are immune infiltrated, they also exhibit multiple features of an immune-suppressed microenviroment. Together, these data unveil a subclass of ERVs whose derepression triggers pathologic innate immune signaling in cancer, with important implications for cancer immunotherapy.
Insights
Certain endogenous retroviruses (ERVs) can be reactivated by cancer therapies, triggering innate immune signaling and promoting tumor growth. This discovery offers new avenues for cancer immunotherapy strategies.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Mesenchymal tumor cells secrete factors that enhance tumor progression and treatment resistance.
- The precise mechanisms driving these pro-tumorigenic effects and treatment resistance are not fully understood.
- Endogenous retroviruses (ERVs) are implicated in various cellular processes, but their role in cancer-associated immune signaling is emerging.
Purpose of the Study:
- To identify specific endogenous retroviruses (ERVs) involved in promoting tumor-associated immune signaling.
- To elucidate the molecular mechanisms by which these ERVs activate innate immune pathways.
- To investigate the clinical relevance of these ERVs in human cancers and their potential as therapeutic targets.
Main Methods:
- Identification and characterization of a novel subclass of ERVs, termed Stimulated 3 prime antisense retroviral coding sequences (SPARCS).
- Analysis of SPARCS' genomic location, orientation, and transcriptional regulation by STAT1 and EZH2.
- Investigation of SPARCS-mediated double-stranded RNA generation and subsequent activation of innate immune sensors (MAVS, STING) and signaling pathways (TBK1, IRF3, STAT1).
- Correlation of SPARCS expression with tumor markers (MHC class I, mesenchymal markers, AXL/MET) and immune infiltration in human tumors and cell lines.
Main Results:
- A subclass of ERVs, SPARCS, was identified, located in 3' untranslated regions and regulated by STAT1 and EZH2.
- IFN-γ exposure induces bi-directional transcription leading to double-stranded RNA production and activation of MAVS/STING-TBK1/IRF3/STAT1 signaling.
- SPARCS expression positively correlates with MHC class I, mesenchymal markers, and AXL/MET expression, and inversely with EZH2.
- SPARCS-high tumors show immune infiltration but also exhibit immune-suppressive features.
Conclusions:
- Derepression of SPARCS triggers pathologic innate immune signaling in cancer cells, contributing to a pro-tumorigenic and immune-suppressed microenvironment.
- SPARCS represent a novel mechanism linking ERV activity to cancer progression and immune evasion.
- Targeting SPARCS-mediated signaling pathways may offer a promising strategy for enhancing cancer immunotherapy.
Related Concept Videos
Retroviruses
What is the Immune System?
Introduction to Innate and Adaptive Immunity
Innate immunity is the body's natural, nonspecific defense system that acts quickly to protect against pathogens. It incorporates physical barriers like skin and mucous membranes and cellular elements such as phagocytes and natural killer cells. This part of our immune system provides an immediate,...
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Retrovirus Life Cycles
Mechanisms of Retrovirus-induced Cancers

